Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Psychooncology. 2013 Dec 16;23(6):626–633. doi: 10.1002/pon.3453

Table 2.

Cognitive Decline From Baseline to Post-treatment by Treatment Group

DOMAIN TEST S (N=11) LE (N=23) HE (N=28) FISHER'S EXACT P (LE vs S) FISHER'S EXACT P (HE vs S)
PERCENT DECLINED
Attention DSpan 0 0 0 * *

Psychomotor Speed DSymbol 0 9 39 1.0 0.017
TMTA 0 4 14 1.0 0.309

Learning and Memory HVLT 0 4 0 1.0 *

Executive TMTB 9 4 7 1.0 1.0

Language COWA 0 0 0 * *

Motor GPD 0 35 39 0.034 0.017
GPND 0 22 14 0.150 0.309

Overall Decline# 0 17 29 0.280 0.08

MEAN (SD)
Number Tests Declined (ANOVA) 0.1 (0.3) 0.8 (0.9) 1.1 (1.0) 0.05 0.005

Note: S=Surveillance; LE=Low Exposure Chemotherapy; HE=High Exposure Chemotherapy; DSpan: WAIS-R Digit Span, DSymbol: WAIS-R Digit Symbol, TMTA: Trail Making Test A, HVLT: Hopkins Verbal Learning Test, TMTB: Trail Making Test B, COWA: Controlled Oral Word Association, GPD/ND: Lafayette Grooved Pegboard Dominant/Non-Dominant Hand

#

Decline on ≥ 2 tests

*

No statistics computed due to zero declines in both groups